A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
Conditions
Neovascular Age-related Macular Degeneration · nAMD
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Peking Union Medical College Hospital, Beijing, China
Beijing Hospital, Beijing, China
Beijing Tongren Hospital, Beijing, China
West China Hospital, Sichuan University, Chengdu, China
Sichuan Provincial People's Hospital, Chengdu, China
Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
The Second Affiliated Hospital of Harbin Medical University, Harbin, China
Qingdao Eye Hospital of Shandong First Medical University, Qingdao, China
Shanghai First People's Hospital, Shanghai, China
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
The First Affiliated Hospital of China Medical University, Shenyang, China
Shanxi Eye Hospital, Taiyuan, China
Tianjin Medical University Eye Hospital, Tianjin, China
Eye Hospital, Wenzhou Medical University, Wenzhou, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China
Xi'an People's Hospital (Xi'an Fourth Hospital), Xi'an, China
Study leads
Clinical Trials
Study Director
Hoffmann-La Roche